Giving your child the right tools to fight TB just got easier! The IMPAACT4TB consortium has played a critical role in introducing the 3HP Dispersible flavoured regimen, a faster and more child-friendly option for preventing TB in children.
Here’s why 3HP Dispersible is a game-changer:
Who Needs 3HP Dispersible? Children from 2 years who have been exposed to someone with TB are at higher risk of developing the infection themselves. 3HP Dispersible is recommended for these children to prevent them from getting sick.
We believe all children deserve the right to a healthy future, free from TB. We need to ensure children can access effective preventive measures like 3HP Dispersible.
Together, let’s shield our children from TB and create a healthier future for all!
This expression of interest (EOI) addresses the global challenge of TB prevention in children. A new dispersible tablet (DT) has been developed to offer a more family-friendly, patient-centered approach to TPT. Unitaid has established the Early Market Access Vehicle (EMAV) to accelerate access to this innovative pediatric formulation. Interested parties are invited to submit an EOI to participate in the EMAV, which aims to secure 85,000 patient courses from the first production phase.
Beginning on 1 December 2023, the Aurum Institute will accept Expressions of Interest (EOI) to the EMAV on a rolling basis through 30 October 2024 (or when total volume commitment is approved, whichever comes first). Parties interested in participation in the EMAV may submit an EOI using the response form (see below) during this time.
Interested partners should review the EOI or reach out to impaact4tb@auruminstitute.org for more information.
Resources for Governments, Clinicians, Healthcare workers, Patients & Communities
